• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

采用粘液-PVPA 模型同步评估体外脂肪分解和渗透,以预测 SNEDDS 中难溶性药物的口服吸收。

Simultaneous assessment of in vitro lipolysis and permeation in the mucus-PVPA model to predict oral absorption of a poorly water soluble drug in SNEDDSs.

机构信息

Drug Transport and Delivery Research Group, Department of Pharmacy, UiT The Arctic University of Norway, Universitetsveien 57, 9037 Tromsø, Norway.

Physiological Pharmaceutics, Department of Pharmacy, University of Copenhagen, Universitetsparken 2-4, 2100 Copenhagen, Denmark.

出版信息

Int J Pharm. 2021 Mar 1;596:120258. doi: 10.1016/j.ijpharm.2021.120258. Epub 2021 Jan 21.

DOI:10.1016/j.ijpharm.2021.120258
PMID:33486034
Abstract

The prediction of the in vivo performance of self-nanoemulsifying drug delivery systems (SNEDDSs) is currently gaining increasing attention. Therefore, the need for reliable in vitro models able to assess the drug solubilization capacity of such formulations upon in vitro lipolysis, as well as to concomitantly evaluate in vitro drug permeation, has become ever so evident. In the current study, the high-throughput in vitro intestinal lipolysis model was combined with the mucus-PVPA in vitro permeation model to study the solubilization capacity of SNEDDSs for the poorly water-soluble drug fenofibrate and to study the consequent drug permeation. Moreover, drug solubilization and permeation were evaluated both in the presence and absence of lipolysis. The results obtained demonstrated that the presence of in vitro lipolysis significantly impacted the solubilization and permeation profiles of fenofibrate compared to its absence. The results were in accordance with already published in vivo data regarding the same fenofibrate-loaded SNEDDSs. Additionally, the correlation between the in vitro permeation data and in vivo plasma concentration in rats was found to be excellent both in the presence and absence of lipolysis (R > 0.98), highlighting the ability of the developed combined in vitro model to predict in vivo drug absorption.

摘要

目前,人们越来越关注自微乳药物传递系统(SNEDDSs)体内性能的预测。因此,人们迫切需要可靠的体外模型,该模型能够评估此类制剂在体外脂肪酶作用下的药物增溶能力,同时评估体外药物渗透。在本研究中,高通量体外肠内脂肪酶解模型与粘蛋白-PVPA 体外渗透模型相结合,研究了 SNEDDSs 对难溶性药物非诺贝特的增溶能力,并研究了随后的药物渗透。此外,在有或没有脂肪酶解的情况下,评估了药物的增溶和渗透。与不存在脂肪酶解相比,获得的结果表明,体外脂肪酶解的存在显著影响了非诺贝特的增溶和渗透特征。这些结果与相同的载有非诺贝特的 SNEDDSs 的已发表的体内数据一致。此外,发现无论是否存在脂肪酶解,体外渗透数据与大鼠体内血浆浓度之间均具有极好的相关性(R>0.98),这突出了所开发的联合体外模型预测体内药物吸收的能力。

相似文献

1
Simultaneous assessment of in vitro lipolysis and permeation in the mucus-PVPA model to predict oral absorption of a poorly water soluble drug in SNEDDSs.采用粘液-PVPA 模型同步评估体外脂肪分解和渗透,以预测 SNEDDS 中难溶性药物的口服吸收。
Int J Pharm. 2021 Mar 1;596:120258. doi: 10.1016/j.ijpharm.2021.120258. Epub 2021 Jan 21.
2
Predicting Oral Absorption of fenofibrate in Lipid-Based Drug Delivery Systems by Combining In Vitro Lipolysis with the Mucus-PVPA Permeability Model.结合体外脂肪酶解和黏膜-PVPA 渗透模型预测脂基给药系统中非诺贝特的口服吸收。
J Pharm Sci. 2021 Jan;110(1):208-216. doi: 10.1016/j.xphs.2020.08.026. Epub 2020 Sep 8.
3
Estimating the Oral Absorption from Self-Nanoemulsifying Drug Delivery Systems Using an In Vitro Lipolysis-Permeation Method.使用体外脂解-渗透法评估自纳米乳化药物递送系统的口服吸收情况。
Pharmaceutics. 2021 Apr 2;13(4):489. doi: 10.3390/pharmaceutics13040489.
4
Lipolysis-Permeation Setup for Simultaneous Study of Digestion and Absorption in Vitro.用于体外同时研究消化和吸收的脂肪分解渗透装置。
Mol Pharm. 2019 Mar 4;16(3):921-930. doi: 10.1021/acs.molpharmaceut.8b00811. Epub 2019 Jan 29.
5
Effect of lipids on absorption of carvedilol in dogs: Is coadministration of lipids as efficient as a lipid-based formulation?脂肪对犬体内卡维地洛吸收的影响:与脂肪制剂相比,同时给予脂肪是否同样有效?
J Control Release. 2019 Jun 28;304:90-100. doi: 10.1016/j.jconrel.2019.04.038. Epub 2019 Apr 29.
6
Using in vitro lipolysis and SPECT/CT in vivo imaging to understand oral absorption of fenofibrate from lipid-based drug delivery systems.采用体外脂肪酶水解和 SPECT/CT 体内成像技术了解贝特类药物从基于脂质的药物传递系统的口服吸收。
J Control Release. 2020 Jan 10;317:375-384. doi: 10.1016/j.jconrel.2019.11.024. Epub 2019 Nov 23.
7
Investigating the correlation between in vivo absorption and in vitro release of fenofibrate from lipid matrix particles in biorelevant medium.研究非诺贝特在生物相关介质中从脂质基质颗粒的体内吸收与体外释放之间的相关性。
Eur J Pharm Sci. 2014 Jan 23;51:204-10. doi: 10.1016/j.ejps.2013.09.022. Epub 2013 Oct 14.
8
Rationalizing the selection of oral lipid based drug delivery systems by an in vitro dynamic lipolysis model for improved oral bioavailability of poorly water soluble drugs.通过体外动态脂解模型优化口服脂质体药物递送系统的选择,以提高难溶性药物的口服生物利用度。
J Control Release. 2008 Jul 2;129(1):1-10. doi: 10.1016/j.jconrel.2008.03.021. Epub 2008 Apr 1.
9
Suitability of Artificial Membranes in Lipolysis-Permeation Assays of Oral Lipid-Based Formulations.人工膜在口服脂质体制剂透皮吸收研究中的适用性。
Pharm Res. 2020 May 20;37(6):99. doi: 10.1007/s11095-020-02833-9.
10
Polymeric Precipitation Inhibitors Promote Fenofibrate Supersaturation and Enhance Drug Absorption from a Type IV Lipid-Based Formulation.聚合物沉淀抑制剂促进非诺贝特过饱和并增强 IV 型脂肪乳剂配方的药物吸收。
Mol Pharm. 2018 Jun 4;15(6):2355-2371. doi: 10.1021/acs.molpharmaceut.8b00206. Epub 2018 May 4.

引用本文的文献

1
Commercially Available Cell-Free Permeability Tests for Industrial Drug Development: Increased Sustainability through Reduction of In Vivo Studies.用于工业药物开发的市售无细胞渗透性测试:通过减少体内研究提高可持续性
Pharmaceutics. 2023 Feb 9;15(2):592. doi: 10.3390/pharmaceutics15020592.
2
Investigation of Self-Emulsifying Drug-Delivery System Interaction with a Biomimetic Membrane under Conditions Relevant to the Small Intestine.研究自乳化给药系统与仿生膜在与小肠相关条件下的相互作用。
Langmuir. 2021 Aug 24;37(33):10200-10213. doi: 10.1021/acs.langmuir.1c01689. Epub 2021 Aug 11.